Introduction: A validated clinical decision tool predictive of favorable functional outcomes following endovascular thrombectomy (EVT) in acute ischemic stroke (AIS) remains elusive. We performed a retrospective case series of patients at our regional Comprehensive Stroke Center, over a 4-year period, who have undergone EVT to elucidate patient characteristics and factors associated with a favorable functional outcome after EVT. Methods: We reviewed all cases of EVT at our institution from 2/2018 - 2/2022 in the extended time window from 6 - 24 hours. Demographic, clinical, imaging, and procedure co-variates were included. A favorable clinical outcome was defined as a modified Rankin scale or 0-2. We included patients with M1 or ICA occlusion treated with EVT within 6-24 hours after symptom onset. We used a univariate and multivariate logistic regression analysis to identify patient factors associated with a favorable clinical outcome at 90 days. Results: Our analysis demonstrates that higher recanalization score based on the mTICI scale (2B-3) was a strong indicator of favorable outcome per both our multivariate and univariate analysis (OR 4.11; CI 1.10 - 15.31; p 0.035). Our data also showed signal that the younger age (p 0.013), lower baseline NIHSS (p 0.043), shorter hospital length of stay (LOS) (p 0.030), and absence of pre-existing hypertension (p 0.026) may also be a predictor of favorable outcome per our univariate analysis. Conclusion: Patients without pre-existing hypertension had more favorable outcomes following EVT in the expanded time window. This is consistent with other multicenter data in the expanded time window that demonstrates greater odds of a poor outcome with elevated pre-, peri-, and post- endovascular treatment blood pressure. Our data also demonstrates mTICI score is a strong predictor of favorable outcome even when controlled for other variables. Other factors that may indicate a favorable outcome include younger age, lower baseline NIHSS, and shorter hospital LOS.

The authors have declared no competing interest.

No external funding was received

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approved by University of Wisconsin SMPH IRB under Protocol ID: 2016-0418

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data underlying the results are available as part of the article. No additional source data is required. Raw data used in analysis is available upon request.